{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:55:12Z","timestamp":1776837312226,"version":"3.51.2"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.012","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T11:53:51Z","timestamp":1689335631000},"page":"985-995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["What is the Path Forward to Treat Hepatitis Delta Virus?"],"prefix":"10.1016","volume":"27","author":[{"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.012_bib1","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/0168-8278(90)90185-T","article-title":"Therapy of chronic delta hepatitis with interferon alfa-2b","volume":"11","author":"Di Bisceglie","year":"1990","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.012_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of chronic hepatitis D with interferon alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.05.012_bib3","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.012_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical practice guidelines Manag. Hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian- Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.cld.2023.05.012_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT- PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"HIDIT-1 Study Group, Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"S1","key":"10.1016\/j.cld.2023.05.012_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.14838","article-title":"New therapies for hepatitis delta virus infection","volume":"41","author":"Loureiro","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.012_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.05.012_bib12","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.cld.2023.05.012_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.012_bib14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a mul-ticenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib16","unstructured":"European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex, Accessed April 15, 2021."},{"key":"10.1016\/j.cld.2023.05.012_bib17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2023.05.012_bib18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.012_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.cld.2023.05.012_bib20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cld.2023.05.012_bib21","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.012_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A\u00a0phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"issue":"S24","key":"10.1016\/j.cld.2023.05.012_bib23","article-title":"PS-039 \u2013 a phase 2 dose- escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.29737","article-title":"Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in\u00a0vivo in Pekin ducks","volume":"67","author":"Quinet","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co- infection (REP 301 and REP 301-LTF): a non-randomised, open- label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hep- atitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2023.05.012_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cld.2023.05.012_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cld.2023.05.012_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drudis.2015.10.021","article-title":"IFN-lambda therapy: current status and future perspectives","volume":"21","author":"Lasfar","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cld.2023.05.012_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.012_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.012_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib34","first-page":"2022","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","author":"Janssen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.012_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/20402066221138705","article-title":"Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens","volume":"30","author":"Gish","year":"2022","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.cld.2023.05.012_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib37","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/cts.12791","article-title":"A\u00a0single and multiple ascending dose study of toll-like receptor 7 agonist (RO7020531) in Chinese healthy volunteers","volume":"13","author":"Luk","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cld.2023.05.012_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coi.2020.04.003","article-title":"HBV as a target for CAR or TCR T\u00a0cell therapy","volume":"66","author":"Bertoletti","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cld.2023.05.012_bib39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1blockade with nivolumab with and without therapeutic vaccination for virally sup- pressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.012_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13656","article-title":"Towards HBV cura- tive therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.05.012_bib41","first-page":"1","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"401","author":"Hoogeveen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2023.05.012_bib42","first-page":"S289","article-title":"Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduc- tion and baseline factors","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2023.05.012_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00836-20","article-title":"ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens","volume":"64","author":"Squires","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2023.05.012_bib44","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepiro- virsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.05.012_bib45","first-page":"S287","article-title":"Safety and antiviral activity of VIR- 2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results","volume":"75","author":"Gane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib46","first-page":"63A","article-title":"Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection","volume":"74","author":"Yuen","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib47","article-title":"Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV\/high HDV prevalence countries","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.012_bib48","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"First international external quality assessment for hepatitis delta virus RNA quantification in plasma","volume":"64","author":"Le Gal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.012_bib49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.012_bib50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib51","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-Related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.05.012_bib52","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.012_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.05.012_bib54","article-title":"Chronic hepatitis D virus infection: developing drugs for treatment","volume":"84","author":"Food and Drug Administration (FDA)","year":"2019","journal-title":"Guidance for Industry"},{"issue":"6","key":"10.1016\/j.cld.2023.05.012_bib55","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:31Z","timestamp":1761069631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000727"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the Path Forward to Treat Hepatitis Delta Virus?","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}